Patents Examined by Niloofar Rahmani
-
Patent number: 11891388Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.Type: GrantFiled: December 22, 2021Date of Patent: February 6, 2024Assignee: Incyte CorporationInventors: Kai Liu, Jun Pan, Alexander Sokolsky, Oleg Vechorkin, Hai Fen Ye, Qinda Ye, Wenqing Yao
-
Patent number: 11884663Abstract: Crystalline forms of emetine dihydrochloride (Compound I dihydrochloride) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms of Compound I dihydrochloride.Type: GrantFiled: December 3, 2021Date of Patent: January 30, 2024Assignee: Acer Therapeutics, Inc.Inventor: John Klopp
-
Patent number: 11878976Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.Type: GrantFiled: March 3, 2022Date of Patent: January 23, 2024Assignee: ELI LILLY AND COMPANYInventors: Adedoyin David Abraham, Desta Doro Bume, Kevin Ronald Condroski, Robert Alan Hazlitt, Timothy Scott Kercher, Andrew Terrance Metcalf, Kaveri Balan Urkalan, Shane Michael Walls, Andrew Karl Dilger
-
Patent number: 11866434Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.Type: GrantFiled: November 5, 2021Date of Patent: January 9, 2024Assignee: Incyte CorporationInventors: Dengjin Wang, Daniel Carper, Zhongjiang Jia, Bo Shen, Joseph A. Sclafani, Robert Wilson, Jiacheng Zhou, Osama Suleiman, Mark Wright
-
Patent number: 11866444Abstract: The present invention provides a compound having the structure:Type: GrantFiled: January 27, 2022Date of Patent: January 9, 2024Assignee: Lixte Biotechnology, Inc.Inventors: John S. Kovach, Robert A. Volkmann, Anthony Marfat
-
Patent number: 11866422Abstract: This invention is directed to novel carbocyclic prolinamide derivatives of Formula (I), and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of age-related macular degeneration (AMD) and related diseases of the eye. These diseases include dry-AMD, wet-AMD, geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells. The invention disclosed herein is further directed to methods of prevention, slowing the progress of, and treatment of dry-AMD, wet-AMD, and geographic atrophy, diabetic retinopathy, retinopathy of prematurity, polypoidal choroidal vasculopathy, and degeneration of retinal or photoreceptor cells, comprising: administration of a therapeutically effective amount of compound of the invention.Type: GrantFiled: July 14, 2021Date of Patent: January 9, 2024Assignee: Orion Ophthalmology LLCInventors: Robert Gomez, Jinyue Ding, Renata Marcella Oballa, David Andrew Powell
-
Patent number: 11866419Abstract: The present invention relates to the following compounds wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.Type: GrantFiled: September 17, 2021Date of Patent: January 9, 2024Assignee: Janssen Sciences Ireland Unlimited CompanyInventors: Jérôme Émile Georges Guillemont, Magali Madeleine Simone Motte, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
-
Patent number: 11858932Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.Type: GrantFiled: June 13, 2023Date of Patent: January 2, 2024Assignee: Spruce Biosciences, Inc.Inventors: Christopher Barnes, David Karpf, Mustafa Noor
-
Patent number: 11851429Abstract: This disclosure is directed, at least in part, to AMPK activators useful for the treatment of conditions or disorders associated with AMPK. In some embodiments, the condition or disorder is associated with the gut-brain axis. In some embodiments, condition or disorder is associated with systemic infection and inflammation from having a leaky gut barrier. In some embodiments, the AMPK activators are gut-restricted compounds. In some embodiments, the AMPK activators are agonists or partial agonists.Type: GrantFiled: January 26, 2022Date of Patent: December 26, 2023Assignee: KALLYOPE, INC.Inventors: Iyassu Sebhat, Shuwen He, Ann Weber, Nancy Thornberry, Lisa Krug, Paul Richards, Brett Lauring
-
Patent number: 11840532Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above compounds.Type: GrantFiled: July 8, 2021Date of Patent: December 12, 2023Assignee: Aligos Therapeutics, Inc.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
-
Patent number: 11840533Abstract: Described herein are pyridinone-based compounds, derivatives thereof, and pharmaceutical formulations thereof. In some aspects, the pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can be administered to a subject in need thereof. In some aspects, pyridinone-based compounds, derivatives thereof, and/or pharmaceutical formulations thereof can modulate an activity and/or a function of a BRD protein and/or BET protein.Type: GrantFiled: May 16, 2022Date of Patent: December 12, 2023Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Yangfeng Li
-
Patent number: 11834451Abstract: This invention is in the field of medicinal chemistry and relates to a new class of small-molecules having a pyrazolopyridine (or similar) structure (e.g., Formula I) which function as inhibitors of the viral protein 2C protein activity and/or expression, and which function as therapeutics for the treatment of viral infection characterized with viral protein 2C activity and/or expression (e.g., non-polio enterovirus infection) (e.g., enterovirus D68 (EV-D68) infection, enterovirus A71 (EV-A71) infection, and coxsackievirus B3 (CVB3) infection.Type: GrantFiled: March 28, 2022Date of Patent: December 5, 2023Assignee: Arizona Board of Regents on Behalf of the University of ArizonaInventors: Jun Wang, Naoya Kitamura
-
Patent number: 11833210Abstract: Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.Type: GrantFiled: October 18, 2021Date of Patent: December 5, 2023Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Jolanta Grembecka, Szymon Klossowski, Jing Deng, Tomasz Cierpicki, Hao Li, Hongzhi Miao, Trupta Purohit, EunGi Kim
-
Patent number: 11834462Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.Type: GrantFiled: April 6, 2022Date of Patent: December 5, 2023Assignee: CRINETICS PHARMACEUTICALS, INC.Inventors: Sangdon Han, Sun Hee Kim, Yunfei Zhu
-
Patent number: 11834449Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.Type: GrantFiled: May 14, 2021Date of Patent: December 5, 2023Assignee: Takeda Pharmaceutical Company LimitedInventors: Jeremy Robert Greenwood, Craig E. Masse
-
Patent number: 11827634Abstract: The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.Type: GrantFiled: December 13, 2021Date of Patent: November 28, 2023Assignee: Janssen Pharmaceutica NVInventors: Wendy Eccles, Michael D. Hack, William M. Jones, Paul J. Krawczuk, Alec D. Lebsack, Daniel J. Pippel, Alexander R. Rovira, Ronald L. Wolin
-
Patent number: 11826430Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.Type: GrantFiled: May 13, 2020Date of Patent: November 28, 2023Assignee: NUVATION BIO INC.Inventors: David Hung, Son Minh Pham, Sarvajit Chakravarty, Jiyun Chen, Jayakanth Kankanala, Jeremy D. Pettigrew, Anup Barde, Anjan Kumar Nayak
-
Patent number: 11827635Abstract: The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.Type: GrantFiled: December 16, 2021Date of Patent: November 28, 2023Assignee: Amgen Inc.Inventors: Mary Chaves, Patricia Lopez, Prashant Agarwal, Albert Amegadzie, Stephanie Azali, Roman Shimanovich, Ron C. Kelly, Darren Leonard Reid
-
Patent number: 11827620Abstract: The present invention relates to new profluorophores and conjugates thereof and their use for the detection of target molecule in a sample, in particular nucleic acid target molecules. The invention relates to new profluorophores and new fluorophores and methods of use thereof particularly useful in the fields of diagnostics and quality control.Type: GrantFiled: October 12, 2017Date of Patent: November 28, 2023Assignee: UNIVERSITE DE GENEVEInventors: Gianpaolo Rando, Nicolas Winssinger, Eric Lindberg, Marcello Anzola
-
Patent number: 11820772Abstract: The present invention relates to polymorphs of the hydrochloride salt of 5-{2-[({8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-yl}carbonyl)-amino]ethoxy}-5-oxopentanoic acid (linaprazan glurate), more specifically Form 1 and Form 2 of the HCl salt of linaprazan glurate. The invention also relates to a process for the preparation of such polymorphs, to pharmaceutical compositions comprising such polymorphs, and to the use of these polymorphs in the treatment or prevention of gastrointestinal inflammatory diseases or gastric acid related diseases, in particular erosive gastroesophageal reflux disease (eGERD).Type: GrantFiled: April 3, 2023Date of Patent: November 21, 2023Assignee: Cinclus Pharma Holding AB (Publ)Inventors: Kjell Jarring, Thomas Larsson, Xingbang Lin, Dan Wang, Mikael Hillgren